Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing